Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santaris Pharma is set to release new clinical data results from the miravirsen Phase 2a study to treat Hepatitis C virus (HCV) infected patients at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.
Subscribe to our email newsletter
Miravirsen, which is developed using Locked Nucleic Acid (LNA) Drug Platform, is an inhibitor of miR-122, a liver specific microRNA that the Hepatitis C virus requires for replication.
The randomized, double-blind, placebo-controlled, ascending multiple-dose Phase 2a study evaluated the safety and tolerability of miravirsen in treatment-naive patients with chronic HCV genotype 1 infection.
The trial demonstrated that miravirsen, a microRNA-targeted drug provided continuous and prolonged anti-viral activity and the patients infected with HCV could tolerat it.
As per the clinical data, miravirsen can be used as a once-weekly treatment for chronic HCV infection.